COGT
insider transactionsCogent Biosciences, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-8.0M
2.8M buy · 10.8M sell
Net value · 365d
-$357.2M
$25.0M in · $382.2M out
Sentiment · 365d
Net selling
6% buying · 94% selling
Open-market trades · 365d
7
2.8M buy · 10.8M sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·C
Fairmount Funds Management LLC
Director
$0
28.0K sh
Own +245%
-
Sell·S
Fairmount Funds Management LLC
Director
$242.6M
7.0M sh · $34.66
Own -56%
-
Exercise·C
Fairmount Funds Management LLC
Director
—
7.0M sh
Own +127%
-
Sell·S
Fairmount Funds Management LLC
Director
$127.4M
3.5M sh · $36.40
Own -39%
-
Grant·A
Director
$0
643 sh
Own New
-
Sell·S
Green John L. KEY
Chief Financial Officer
$3.0M
77.0K sh · $38.68
Own -37%
-
Sell·S
Chief Medical Officer
$3.2M
82.6K sh · $38.70
Own -38%
-
Sell·S
Chief Scientific Officer
$3.5M
90.0K sh · $38.74
Own -39%
-
Sell·S
Chief Legal Officer
$2.5M
65.0K sh · $38.70
Own -37%
-
Grant·A
Robbins Andrew R KEY
President and CEO
$0
245.0K sh
Own New
-
Grant·A
Robbins Andrew R KEY
President and CEO
$0
840.0K sh
Own +454%
-
Grant·A
Robbins Andrew R KEY
President and CEO
$0
185.0K sh
Own New
-
Other·F
Robbins Andrew R KEY
President and CEO
$14.5M
367.5K sh · $39.45
Own -36%
-
Grant·A
Green John L. KEY
Chief Financial Officer
$0
65.0K sh
Own New
-
Grant·A
Green John L. KEY
Chief Financial Officer
$0
300.0K sh
Own +557%
-
Grant·A
Green John L. KEY
Chief Financial Officer
$0
50.0K sh
Own +1302%
-
Other·F
Green John L. KEY
Chief Financial Officer
$5.7M
145.0K sh · $39.45
Own -41%
-
Grant·A
Chief Commercial Officer
$0
65.0K sh
Own New
-
Grant·A
Chief Commercial Officer
$0
50.0K sh
Own +105%
-
Other·F
Chief Commercial Officer
$3.7M
94.8K sh · $39.45
Own -30%
-
Grant·A
Chief Commercial Officer
$0
214.0K sh
Own +220%
-
Grant·A
Chief Legal Officer
$0
55.0K sh
Own New
-
Other·F
Chief Legal Officer
$5.0M
125.6K sh · $39.45
Own -42%
-
Grant·A
Chief Legal Officer
$0
260.0K sh
Own +650%
-
Grant·A
Chief Legal Officer
$0
40.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
65.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
50.0K sh
Own +3858%
-
Grant·A
Chief Medical Officer
$0
320.0K sh
Own +624%
-
Other·F
Chief Medical Officer
$6.1M
154.7K sh · $39.45
Own -42%
-
Grant·A
Chief Scientific Officer
$0
65.0K sh
Own New
-
Grant·A
Chief Scientific Officer
$0
320.0K sh
Own +640%
-
Other·F
Chief Scientific Officer
$5.5M
140.0K sh · $39.45
Own -38%
-
Grant·A
Chief Scientific Officer
$0
50.0K sh
Own New
-
Grant·A
Director
$0
1.6K sh
Own New
-
Buy·P
Fairmount Funds Management LLC
Director
$25.0M
2.8M sh · $9.00
Own +45%
-
Grant·A
Director
$0
3.3K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Mar 31, 2026 | Fairmount Funds Management LLC | Exercise C | 28.0K | $0 |
| Mar 31, 2026 | Fairmount Funds Management LLC | Sell S | 7.0M | $242.6M |
| Mar 31, 2026 | Fairmount Funds Management LLC | Exercise C | 7.0M | — |
| Jan 22, 2026 | Fairmount Funds Management LLC | Sell S | 3.5M | $127.4M |
| Jan 1, 2026 | Ferrante Karen Jean | Grant A | 643 | $0 |
| Dec 26, 2025 | Green John L. KEY | Sell S | 77.0K | $3.0M |
| Dec 26, 2025 | Sachs Jessica | Sell S | 82.6K | $3.2M |
| Dec 26, 2025 | Robinson John Edward | Sell S | 90.0K | $3.5M |
| Dec 26, 2025 | Kearns Evan | Sell S | 65.0K | $2.5M |
| Dec 17, 2025 | Robbins Andrew R KEY | Grant A | 245.0K | $0 |
| Dec 17, 2025 | Robbins Andrew R KEY | Grant A | 840.0K | $0 |
| Dec 17, 2025 | Robbins Andrew R KEY | Grant A | 185.0K | $0 |
| Dec 17, 2025 | Robbins Andrew R KEY | Other F | 367.5K | $14.5M |
| Dec 17, 2025 | Green John L. KEY | Grant A | 65.0K | $0 |
| Dec 17, 2025 | Green John L. KEY | Grant A | 300.0K | $0 |
| Dec 17, 2025 | Green John L. KEY | Grant A | 50.0K | $0 |
| Dec 17, 2025 | Green John L. KEY | Other F | 145.0K | $5.7M |
| Dec 17, 2025 | Pinnow Cole | Grant A | 65.0K | $0 |
| Dec 17, 2025 | Pinnow Cole | Grant A | 50.0K | $0 |
| Dec 17, 2025 | Pinnow Cole | Other F | 94.8K | $3.7M |
| Dec 17, 2025 | Pinnow Cole | Grant A | 214.0K | $0 |
| Dec 17, 2025 | Kearns Evan | Grant A | 55.0K | $0 |
| Dec 17, 2025 | Kearns Evan | Other F | 125.6K | $5.0M |
| Dec 17, 2025 | Kearns Evan | Grant A | 260.0K | $0 |
| Dec 17, 2025 | Kearns Evan | Grant A | 40.0K | $0 |
| Dec 17, 2025 | Sachs Jessica | Grant A | 65.0K | $0 |
| Dec 17, 2025 | Sachs Jessica | Grant A | 50.0K | $0 |
| Dec 17, 2025 | Sachs Jessica | Grant A | 320.0K | $0 |
| Dec 17, 2025 | Sachs Jessica | Other F | 154.7K | $6.1M |
| Dec 17, 2025 | Robinson John Edward | Grant A | 65.0K | $0 |
| Dec 17, 2025 | Robinson John Edward | Grant A | 320.0K | $0 |
| Dec 17, 2025 | Robinson John Edward | Other F | 140.0K | $5.5M |
| Dec 17, 2025 | Robinson John Edward | Grant A | 50.0K | $0 |
| Oct 1, 2025 | Ferrante Karen Jean | Grant A | 1.6K | $0 |
| Jul 10, 2025 | Fairmount Funds Management LLC | Buy P | 2.8M | $25.0M |
| Jul 1, 2025 | Ferrante Karen Jean | Grant A | 3.3K | $0 |
About COGT insider trading
This page tracks insider transactions for Cogent Biosciences, Inc. (COGT) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.